CIPLA.BO - Cipla Limited

BSE - BSE Real Time Price. Currency in INR
570.35
+6.90 (+1.22%)
At close: 3:58PM IST
Stock chart is not supported by your current browser
Previous close563.45
Open566.00
Bid570.05 x 0
Ask0.00 x 0
Day's range559.95 - 572.25
52-week range483.75 - 678.00
Volume86,434
Avg. volume247,309
Market cap460.026B
Beta (3Y monthly)0.16
PE ratio (TTM)30.13
EPS (TTM)18.93
Earnings date6 Aug 2019 - 10 Aug 2019
Forward dividend & yield3.00 (0.53%)
Ex-dividend date2018-08-13
1y target estN/A
  • Free Press Journal24 days ago

    Cipla gets USFDA nod for pulmonary arterial hypertension drug

    Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan tablets, indicated for the treatment of pulmonary arterial hypertension.

  • Free Press Journal3 months ago

    Cipla to launch cinacalcet hydrochloride tablets in US

    Drug major Cipla and its subsidiary Cipla USA Wednesday announced a phased launch of generic cinacalcet hydrochloride tablets.

  • Reuters4 months ago

    Cipla third-quarter profit falls as lean India sales, tax cost weigh

    Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic ...

  • Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar
    Business Wire4 months ago

    Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

    Bio-Thera Solutions Ltd announced today that it has reached a licensing agreement with Cipla Limited for BAT1706, its bevacizumab biosimilar, under which Cipla will have exclusive rights to distribute and market the drug in select emerging markets.

  • Cipla Slumps To Five-Month Low As Analysts See Strain On Profitability   
    Bloomberg Quint7 months ago

    Cipla Slumps To Five-Month Low As Analysts See Strain On Profitability   

    Analsyts cut FY19 earnings per share estimates for Cipla in the range of 10-25 percent.

  • Cipla stock clocks sharpest intra day fall in one year post Q2 earnings
    India Today7 months ago

    Cipla stock clocks sharpest intra day fall in one year post Q2 earnings

    The stock fell up to 8.2% to intra day low of 558.10 compared to its previous close of 608.50 on the BSE. The stock has lost 7.44% since the beginning of this year and fallen 12.13% during the last one year.

  • Reuters7 months ago

    Cipla warns of headwinds in second half after second-quarter profit miss

    Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of ...

  • Reuters8 months ago

    Ugandan unit of Indian drugs firm Cipla raises $43.8 million in IPO: Renaissance Capital

    The Ugandan unit of India's pharmaceutical giant Cipla raised 167 billion Ugandan shillings ($43.8 million) from its oversubscribed initial public offering (IPO), an investment bank that helped advise on the transaction said on Monday. Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 percent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings and closed the first day of trading up 2.1 percent at 262 Ugandan shillings.

  • What Kind Of Shareholders Own Cipla Limited (NSE:CIPLA)?
    Simply Wall St.9 months ago

    What Kind Of Shareholders Own Cipla Limited (NSE:CIPLA)?

    A look at the shareholders of Cipla Limited (NSE:CIPLA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • Drugmaker Cipla's Ugandan unit prices IPO
    Reuters9 months ago

    Drugmaker Cipla's Ugandan unit prices IPO

    The Ugandan unit of Indian drugmaker Cipla priced its initial public offering on Tuesday at 256.5 shillings per share, aiming to raise $45 million from its listing on the Kampala stock exchange next month. Cipla Quality Chemical Industries, which is majority owned by India's third-largest drugmaker, is selling 657,179,319 shares, or an 18 percent stake in the company. Chief Executive Officer Emmanuel Katongole, in a statement, said the IPO would enable Ugandan investors to share in the company's success.

  • Reuters9 months ago

    Cipla first-quarter profit trumps estimates on strong domestic growth

    Indian drugmaker Cipla Ltd posted quarterly profit well above analysts' expectations, helped by strong growth in the domestic market. Net profit rose 10.4 percent from a year earlier to 4.51 billion rupees ...

  • Reuters10 months ago

    Uganda's Cipla Quality Chemical Industries says plans IPO, listing

    Ugandan drugmaker Cipla Quality Chemical Industries Ltd said on Thursday it plans an initial public offering and a listing on the East African country's stock exchange. The company said each of its shareholders would be "selling a minority of their stakes" in the IPO and that the transaction and potential listing had received regulatory approvals. The drug maker, majority-owned by India's pharmaceutical giant Cipla, was established in 2005 and has a manufacturing plant in the Ugandan capital Kampala.

  • What Should Investors Know About Cipla Limited’s (NSE:CIPLA) Future?
    Simply Wall St.11 months ago

    What Should Investors Know About Cipla Limited’s (NSE:CIPLA) Future?

    Cipla Limited’s (NSE:CIPLA) announced its latest earnings update in March 2018, which indicated that the company gained from a robust tailwind, leading to a double-digit earnings growth of 40.16%. InvestorsRead More...

  • Cipla Shifts Focus To India To Drive Growth
    Bloomberg Quint11 months ago

    Cipla Shifts Focus To India To Drive Growth

    Cipla is looking at a billion dollar consolidated revenue for the domestic market in FY19.